Literature DB >> 3907228

Metabolic effects of intranasally administered glucagon: comparison with intramuscular and intravenous injection.

A E Pontiroli, M Alberetto, G Pozza.   

Abstract

Intranasal administration of glucagon, 1 mg, plus sodium glycocholate 15 mg as a surfactant, raised blood glucose levels and plasma levels of immunoreactive glucagon (IRG) and immunoreactive insulin (IRI). Spray solutions were more effective than drops, and neither the surfactant alone nor glucagon alone had any effect. Blood glucose levels were similarly affected by intravenous glucagon, while intramuscular glucagon was slightly more effective. The highest IRG concentrations were reached after intravenous administration, while intramuscular injection of glucagon was accompanied by the highest IRI release. These data indicate that intranasal administration of glucagon exerts metabolic effects similar to intramuscular and intravenous administrations. Further studies are needed to improve bioavailability and efficacy of intranasally administered glucagon.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3907228     DOI: 10.1007/bf02590783

Source DB:  PubMed          Journal:  Acta Diabetol Lat        ISSN: 0001-5563


  7 in total

1.  Corticotropic action of an intra-nasally applied synthetic ACTH derivative.

Authors:  G Baumann; A Walser; P A Desaulles; F J Paesi; L Geller
Journal:  J Clin Endocrinol Metab       Date:  1976-01       Impact factor: 5.958

2.  Comparison of plasma levels of luteinizing hormone releasing hormone in men after intravenous or intranasal administration.

Authors:  G Fink; G Gennser; P Liedholm; J Thorell; J Mulder
Journal:  J Endocrinol       Date:  1974-11       Impact factor: 4.286

3.  Absorption of insulin from the human small intestine.

Authors:  C W Crane; G R Luntz
Journal:  Diabetes       Date:  1968-10       Impact factor: 9.461

4.  Intranasal glucagon raises blood glucose concentrations in healthy volunteers.

Authors:  A E Pontiroli; M Alberetto; G Pozza
Journal:  Br Med J (Clin Res Ed)       Date:  1983-08-13

5.  Glucagon and catecholamine secretion during hypoglycemia in normal and diabetic man.

Authors:  J W Benson; D G Johnson; J P Palmer; P L Werner; J W Ensinck
Journal:  J Clin Endocrinol Metab       Date:  1977-03       Impact factor: 5.958

6.  Insulin administered intranasally as an insulin-bile salt aerosol. Effectiveness and reproducibility in normal and diabetic subjects.

Authors:  A C Moses; G S Gordon; M C Carey; J S Flier
Journal:  Diabetes       Date:  1983-11       Impact factor: 9.461

7.  Insulin given intranasally induces hypoglycaemia in normal and diabetic subjects.

Authors:  A E Pontiroli; M Alberetto; A Secchi; G Dossi; I Bosi; G Pozza
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-30
  7 in total
  11 in total

1.  The molecular weight dependence of nasal absorption: the effect of absorption enhancers.

Authors:  M D Donovan; G L Flynn; G L Amidon
Journal:  Pharm Res       Date:  1990-08       Impact factor: 4.200

2.  A new non-invasive method for treating insulin-reaction: intranasal lyophylized glucagon.

Authors:  G Slama; C Alamowitch; N Desplanque; M Letanoux; P Zirinis
Journal:  Diabetologia       Date:  1990-11       Impact factor: 10.122

Review 3.  Intranasal drug delivery. Potential advantages and limitations from a clinical pharmacokinetic perspective.

Authors:  A E Pontiroli; A Calderara; G Pozza
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

Review 4.  Intranasal glucagon: a promising approach for treatment of severe hypoglycemia.

Authors:  Antonio E Pontiroli
Journal:  J Diabetes Sci Technol       Date:  2014-11-10

5.  Nasal administration of glucagon and human calcitonin to healthy subjects: a comparison of powders and spray solutions and of different enhancing agents.

Authors:  A E Pontiroli; M Alberetto; A Calderara; E Pajetta; G Pozza
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

6.  Pharmacokinetics of intranasal, intramuscular and intravenous glucagon in healthy subjects and diabetic patients.

Authors:  A E Pontiroli; A Calderara; M G Perfetti; S R Bareggi
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  Glucose recovery after intranasal glucagon during hypoglycaemia in man.

Authors:  A Hvidberg; R Djurup; J Hilsted
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

8.  Intranasal glucagon treatment relieves hypoglycaemia in children with type 1 (insulin-dependent) diabetes mellitus.

Authors:  E Stenninger; J Aman
Journal:  Diabetologia       Date:  1993-10       Impact factor: 10.122

9.  Intranasal versus injectable glucagon for hypoglycemia in type 1 diabetes: systematic review and meta-analysis.

Authors:  Antonio E Pontiroli; Elena Tagliabue
Journal:  Acta Diabetol       Date:  2020-02-06       Impact factor: 4.280

10.  Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.

Authors:  Michael R Rickels; Katrina J Ruedy; Nicole C Foster; Claude A Piché; Hélène Dulude; Jennifer L Sherr; William V Tamborlane; Kathleen E Bethin; Linda A DiMeglio; R Paul Wadwa; Andrew J Ahmann; Michael J Haller; Brandon M Nathan; Santica M Marcovina; Emmanouil Rampakakis; Linyan Meng; Roy W Beck
Journal:  Diabetes Care       Date:  2015-12-17       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.